MA53648A - Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase - Google Patents
Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidaseInfo
- Publication number
- MA53648A MA53648A MA053648A MA53648A MA53648A MA 53648 A MA53648 A MA 53648A MA 053648 A MA053648 A MA 053648A MA 53648 A MA53648 A MA 53648A MA 53648 A MA53648 A MA 53648A
- Authority
- MA
- Morocco
- Prior art keywords
- glucopyranosidase
- desoxy
- acetamido
- glycoprotein
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733484P | 2018-09-19 | 2018-09-19 | |
| US201862750000P | 2018-10-24 | 2018-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53648A true MA53648A (fr) | 2021-07-28 |
Family
ID=68073263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053648A MA53648A (fr) | 2018-09-19 | 2019-09-18 | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12180205B2 (fr) |
| EP (1) | EP3853226A1 (fr) |
| JP (2) | JP7606960B2 (fr) |
| KR (1) | KR20210060513A (fr) |
| CN (2) | CN119219621A (fr) |
| AU (1) | AU2019344922B2 (fr) |
| BR (1) | BR112021004739A2 (fr) |
| CA (1) | CA3113009A1 (fr) |
| CL (1) | CL2021000646A1 (fr) |
| CO (1) | CO2021004873A2 (fr) |
| CR (1) | CR20210181A (fr) |
| IL (2) | IL315564A (fr) |
| JO (1) | JOP20210036A1 (fr) |
| MA (1) | MA53648A (fr) |
| MX (1) | MX2021003232A (fr) |
| PE (1) | PE20211591A1 (fr) |
| PH (1) | PH12021550439A1 (fr) |
| SG (1) | SG11202102379XA (fr) |
| UY (1) | UY38376A (fr) |
| WO (1) | WO2020061150A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230061395A (ko) * | 2020-08-03 | 2023-05-08 | 바이오젠 엠에이 인코포레이티드 | O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제의 결정질 형태 |
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP1351936A1 (fr) | 2001-01-15 | 2003-10-15 | Glaxo Group Limited | Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl |
| US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
| RU2505540C2 (ru) | 2008-12-23 | 2014-01-27 | Эббви Инк. | Антивирусные соединения |
| WO2011143495A1 (fr) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Composés d'hétéroaryloxyhétérocyclyle convenant comme inhibiteurs de la pde10 |
| US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013075084A1 (fr) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| WO2013078320A1 (fr) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| EP2812001B1 (fr) | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulateurs d'enzymes de modification par méthylation, leurs compositions et utilisations |
| WO2013170072A2 (fr) | 2012-05-09 | 2013-11-14 | Neurop, Inc. | Composés pour le traitement de troubles neurologiques |
| KR20150079711A (ko) | 2012-10-31 | 2015-07-08 | 알렉토스 테라퓨틱스 인크. | 글리코시다아제 저해제 및 이의 용도 |
| ME02730B (fr) | 2013-02-11 | 2017-10-20 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| CA2899088C (fr) | 2013-03-14 | 2022-12-20 | Merck Patent Gmbh | Composes de thiazole et d'oxazole en tant qu'inhibiteurs de glycosidase |
| EP2970305B1 (fr) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| EP3033334A1 (fr) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées |
| DK3092236T3 (en) | 2014-01-06 | 2020-11-30 | Rhizen Pharmaceuticals S A | Nye glutaminaseinhibitorer |
| WO2016107603A1 (fr) | 2015-01-01 | 2016-07-07 | 成都贝斯凯瑞生物科技有限公司 | Dérivés hétérocycliques contenant de l'azote substitué et leurs applications |
| CN110300752A (zh) * | 2016-12-16 | 2019-10-01 | 詹森药业有限公司 | 单环oga抑制剂化合物 |
| CN110312716A (zh) | 2016-12-16 | 2019-10-08 | 詹森药业有限公司 | 双环oga抑制剂化合物 |
| TWI654978B (zh) * | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| MX2020009530A (es) | 2018-03-14 | 2021-01-15 | Biogen Ma Inc | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. |
| US11459324B2 (en) | 2018-03-14 | 2022-10-04 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
| US20210300900A1 (en) | 2018-06-20 | 2021-09-30 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
-
2019
- 2019-09-18 AU AU2019344922A patent/AU2019344922B2/en active Active
- 2019-09-18 MA MA053648A patent/MA53648A/fr unknown
- 2019-09-18 JP JP2021515045A patent/JP7606960B2/ja active Active
- 2019-09-18 WO PCT/US2019/051661 patent/WO2020061150A1/fr active Application Filing
- 2019-09-18 CN CN202411009108.7A patent/CN119219621A/zh active Pending
- 2019-09-18 PE PE2021000333A patent/PE20211591A1/es unknown
- 2019-09-18 SG SG11202102379XA patent/SG11202102379XA/en unknown
- 2019-09-18 JO JOP/2021/0036A patent/JOP20210036A1/ar unknown
- 2019-09-18 CN CN201980060829.1A patent/CN113166137B/zh active Active
- 2019-09-18 MX MX2021003232A patent/MX2021003232A/es unknown
- 2019-09-18 BR BR112021004739-5A patent/BR112021004739A2/pt unknown
- 2019-09-18 EP EP19779339.1A patent/EP3853226A1/fr active Pending
- 2019-09-18 UY UY0001038376A patent/UY38376A/es unknown
- 2019-09-18 IL IL315564A patent/IL315564A/en unknown
- 2019-09-18 IL IL281514A patent/IL281514B2/en unknown
- 2019-09-18 CR CR20210181A patent/CR20210181A/es unknown
- 2019-09-18 CA CA3113009A patent/CA3113009A1/fr active Pending
- 2019-09-18 US US17/276,502 patent/US12180205B2/en active Active
- 2019-09-18 KR KR1020217010451A patent/KR20210060513A/ko not_active Application Discontinuation
-
2021
- 2021-03-02 PH PH12021550439A patent/PH12021550439A1/en unknown
- 2021-03-16 CL CL2021000646A patent/CL2021000646A1/es unknown
- 2021-04-16 CO CONC2021/0004873A patent/CO2021004873A2/es unknown
-
2024
- 2024-05-24 US US18/673,619 patent/US20240308995A1/en active Pending
- 2024-09-27 JP JP2024168726A patent/JP2025011144A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL281514B1 (en) | 2024-10-01 |
| WO2020061150A1 (fr) | 2020-03-26 |
| SG11202102379XA (en) | 2021-04-29 |
| KR20210060513A (ko) | 2021-05-26 |
| US12180205B2 (en) | 2024-12-31 |
| EP3853226A1 (fr) | 2021-07-28 |
| CR20210181A (es) | 2021-07-01 |
| IL281514B2 (en) | 2025-02-01 |
| JP2022500472A (ja) | 2022-01-04 |
| JP7606960B2 (ja) | 2024-12-26 |
| IL315564A (en) | 2024-11-01 |
| JP2025011144A (ja) | 2025-01-23 |
| CA3113009A1 (fr) | 2020-03-26 |
| BR112021004739A2 (pt) | 2021-06-01 |
| PH12021550439A1 (en) | 2021-11-29 |
| PE20211591A1 (es) | 2021-08-18 |
| US20240308995A1 (en) | 2024-09-19 |
| CN113166137B (zh) | 2024-08-16 |
| CN119219621A (zh) | 2024-12-31 |
| AU2019344922B2 (en) | 2025-02-06 |
| US20220041586A1 (en) | 2022-02-10 |
| MX2021003232A (es) | 2021-07-16 |
| TW202031651A (zh) | 2020-09-01 |
| CL2021000646A1 (es) | 2021-09-03 |
| JOP20210036A1 (ar) | 2021-02-25 |
| CO2021004873A2 (es) | 2021-07-30 |
| AU2019344922A1 (en) | 2021-03-25 |
| UY38376A (es) | 2020-04-30 |
| CN113166137A (zh) | 2021-07-23 |
| IL281514A (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54543A (fr) | Inhibiteurs de kif18a | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| MA51066A (fr) | Inhibiteurs d'intégrine | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| EP3761992A4 (fr) | Inhibiteurs d'arginase | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| DK3774817T3 (da) | Bcl6-hæmmere | |
| EP3801499A4 (fr) | Inhibiteurs de sarm1 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA50906A (fr) | Inhibiteurs d'immunoprotéasome | |
| EP3786157A4 (fr) | Inhibiteur de l'interaction protéine-protéine mll1-wdr5 de phényle triazole | |
| EP3919491A4 (fr) | Inhibiteur d'akt | |
| DK3737403T5 (da) | Modificerede adenovira | |
| EP3999517A4 (fr) | Inhibiteurs de cd73 | |
| EP3906685A4 (fr) | Accès aléatoire basé sur une sous-image | |
| PL3810633T3 (pl) | Związki | |
| MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
| DK3738452T3 (da) | Fordamper |